Reported net earnings attributable to Walgreens Boots
Alliance decreased 23.6% to $1 billion while EPS fell 16.5% to $1.13 versus
last year. Adjusted earnings dropped 12.1% to $1.3 billion while EPS declined
4% to $1.47.
Sales in the Retail Pharmacy USA segment grew 2.3%
to $26.5 billion from last year. Excluding store optimisation impacts related
to the Rite Aid stores acquisition, organic sales rose 2.9%. The majority of
the division’s sales came from pharmacy sales, which grew 4.3% year-over-year,
helped by higher brand inflation and prescription volume as well as strength in
central specialty. Retail sales fell 2.9% in the quarter.
Retail Pharmacy International sales fell 7.3% to
$2.8 billion versus the prior-year period, reflecting an adverse currency
impact of 5.7%. The Pharmaceutical Wholesale unit saw a drop of 1.7% in sales
to $5.9 billion, due to a 10% adverse currency impact.
Walgreens maintained adjusted EPS guidance for
fiscal 2019 of roughly flat, at constant currency rates. On a reported currency
basis, the company anticipates approx. $0.06 per share of adverse currency
impact.
During the quarter, the company declared a quarterly dividend of $0.44 per share, payable on June 12, 2019 to stockholders of record as of May 18, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.